Table 3.
Adverse events occurring in >2 subjects
| AE | No. (%) of subjects |
||||||
|---|---|---|---|---|---|---|---|
| Placebo (n = 10) | GSK2248761 once-daily dose (mg) |
Total (n = 48) | |||||
| 30 (n = 6) | 100 (n = 8) | 200 (n = 8) | 400 (n = 8) | 800 (n = 8) | |||
| Any AE | 7 (70) | 4 (67) | 7 (88) | 5 (63) | 7 (88) | 2 (25) | 32 (67) |
| Headache | 5 (50) | 0 | 4 (50) | 2 (25) | 3 (38) | 2 (25) | 16 (33) |
| Dyspepsia | 3 (30) | 0 | 3 (38) | 1 (13) | 2 (25) | 0 | 9 (19) |
| Nausea | 2 (20) | 0 | 0 | 1 (13) | 1 (13) | 1 (13) | 5 (10) |
| Diarrhea | 1 (10) | 2 (33) | 0 | 0 | 1 (13) | 0 | 4 (8) |
| Back pain | 0 | 0 | 1 (13) | 0 | 1 (13) | 1 (13) | 3 (6) |
| Toothache | 0 | 0 | 0 | 2 (25) | 0 | 1 (13) | 3 (6) |
| Anxiety | 0 | 1 (17) | 0 | 0 | 1 (13) | 1 (13) | 3 (6) |
| Nasopharyngitis | 1 (10) | 1 (17) | 0 | 0 | 1 (13) | 0 | 3 (6) |